
Revvity Introduces Pin-point™ Base Editing Reagents to Researchers to Accelerate Genomic Discovery
Revvity, Inc. (NYSE: RVTY) announced the launch of its Pin-point™ base editing platform reagents. This technology platform allows researchers with access to advanced gene editing techniques, opening new avenues for preclinical laboratories. Base editing, a pivotal advancement in CRISPR gene editing, allows for safe and precise multi-gene editing. It holds the potential to enhance functional genomics insights for drug development, streamline cell therapy development and manufacturing, and tackle rare inherited genetic diseases and cancer.
Michelle Fraser, Head of Cell and Gene Therapy at Revvity, emphasizes the significance of this technology: “Base editing allows for the safe and precise correction of single base changes at multiple target sites simultaneously. This streamlined approach has immense potential for developing cell therapies targeting rare inherited genetic diseases, cancer, and creating universal donor cells for allogeneic cell therapies.”
The Pin-point™ Base Editing platform is an advanced gene editing technology that enhances the precision of base editing in genomic DNA. It allows simultaneous modification of multiple genes and is useful in human disease modeling, gene silencing, mutation correction, and cell therapy optimization. The platform comprises three key components: guide RNA, modified Cas9, and a recruited deaminase enzyme. Together, they enable precise base changes in the DNA. Compared to traditional CRISPR technologies, Pin-point base editing is safer for therapeutic use as it nicks only one DNA strand, reducing the risk of unwanted genetic changes downstream.
The initial reagents launch includes mRNAs for nCas9 and rat APOBEC, along with three guide RNAs designed to knockout the TRAC, CD52, and PDCD1 loci. These reagents have been extensively validated and proven effective in T-cells and induced pluripotent stem cells (iPSCs). Researchers can also order custom guides for other targets through Revvity’s Dharmacon™ custom gRNA ordering tool for the Pin-point base editing platform, enabling diverse research applications. Previously, researchers had to either custom-order base editing reagents or rely on non-profit laboratories for individual components. With the newly launched reagents, scientists can fully evaluate the Pin-point base editing platform in-house.
Earlier this year, Revvity entered into a non-exclusive license agreement with AstraZeneca, providing the biopharmaceutical company access to its Pin-point base editing technology. This collaboration aims to advance AstraZeneca’s work in cell therapy for cancer and immune-mediated diseases, further demonstrating the platform’s potential for therapeutic applications.